P-0024 The Efficacy and Tolerability of Modified DCF in Patients with Advanced or Recurrent Gastric Cancer: A Retrospective Analysis

Abstract

ABSTRACT Introduction Although docetaxel, cisplatin and 5FU (DCF) significantly has improved TTP, and OS in gastric cancer patients, the use of DCF has restricted because of severe toxicities. In real world, the dose of DCF has frequently modified according to clinician’s experiences and intuition. In this report, we introduce new modified DCF (mDCF) regimen and report efficacy and tolerability of mDCF in advanced or recurrent gastric cancer. Methods Total 24 patients with advanced or recurrent gastric cancer treated with mDCF at Seoul Paik Hospital between Mar 2007 and June 2010 were reviewed. Treatment protocol was 60mg/m2 of docetaxel, 50mg/m2 of cisplatin on D1, and 950mg/m2/day of 5FU continuous infusion on D1-3 until disease progression or intolerance to chemotherapy. All clinical data were collected retrospectively. Results Of 24, 22 patients were assessable for response. The ORR was 37.3 % (9/24), including 1 CR, and TCR 70.8 % (17/24). Median PFS and OS were 6.13 months (95% CI, 2.5-9.7) and 8.2 months (95% CI, 3.1-13.3). Grade 3 or 4 hematologic toxicities were neutropenia in 10 patients (41.7%), anemia in 3 patients (12.5%) and thrombocytopenia 4 patients (16.7%). The treatment related death occurred in 2 patients (8.3%) due to sepsis. The median cycle of chemotherapy was 6 (range: 1-15). Half of 24 patients (50%) received chemotherapy more than 8 cycles, and 2 patients (8.3%) received 15 cycles with tolerable toxicities. In this extended chemotherapy group, median PFS and OS were 10.9 months (95% CI, 4.4-17.3) and 14.1 months (95%CI, 6.7-21.5). Conclusion The presented mDCF showed favorable ORR, TCR, and acceptable toxicity profiles in patients with advanced gastric cancer. Chemotherapy with mDCF was safely used more than 8 cycles in patients who responded to mDCF. This extended mDCF could be an alternative choice after 4 or 6 cycles mDCF.